PUBBLICAZIONI / PUBLICATIONS IN PEER-REVIEWED JOURNALS

 

  1. Spina F, Radice T, De Philippis C, Soldarini M, Di Chio MC, Dodero A, Guidetti A,    Viviani S, Corradini P.  Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival.doi: 10.1080/10428194.2018.1459607.
  2. Tiacci E, Ladewig E, Schiavoni G, Penson A, Fortini E, Pettirossi V, Wang Y, Rosseto A, Venanzi A, Vlasevska S, Pacini R, Piattoni S, Tabarrini A, Pucciarini A, Bigerna B, Santi A, Gianni AM, Viviani S, Cabras A, Ascani S, Crescenzi B, Mecucci C, Pasqualucci L, Rabadan R, Falini B. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. Blood. 2018 May 31;131(22):2454-2465. doi: 10.1080/10428194.2018.1459607.
  3. Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.Blood. 2018;132(25):2639-2642. doi: 10.1182/blood-2018-07-861641.
  4. Viviani S, Guidetti AS. Efficacy of antibody-drug conjugate brentuximab vedotin in treating Hodgkin's lymphoma. Expert Opin Biol Ther. 2018;18(8):841-849. doi: 10.1080/14712598.2018.1499723.
  5. Carella AM, Corradini P, Mussetti A, Ricardi U, Vitolo U, Viviani S. Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors. Ann Hematol. 2018;97(8):1301-1315. doi: 10.1007/s00277-018-3366-x
  6. Gallamini A, Viviani S, Pavoni C, Rambaldi A. Reply to H.J.A. Adams et al and C. Mesguich et al.J Clin Oncol. 2018;36(20):2125-2126. doi: 10.1200/JCO.2018.78.7762.
  7. Viviani S, Tabanelli V, Pileri SA. The pathobiology and treatment of Hodgkin lymphoma. Where do we go from Gianni Bonadonna's lesson? Tumori 2017; 22:0. doi: 10.5301./tj.5000608.
  8. Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mulé A, Picardi M, Romano A, Cantonetti M, La Nasa G, Trentin L, Bolis S, Rapezzi D, Battistini R, Gottardi D, Gavarotti P, Corradini P, Cimminiello M, Schiavotto C, Parvis G, Zanotti R, Gini G, Ferreri AJM, Viero P, Miglino M, Billio A, Avigdor A, Biggi A, Fallanca F, Ficola U, Gregianin M, Chiaravalloti A, Prosperini G, Bergesio F, Chauvie S, Pavoni C, Gianni AM, Rambaldi A. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.J Clin Oncol. 2018 Feb 10;36(5):454-462. doi: 10.1200/JCO.2017.75.2543.
  9. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984.
  10. Guidetti A, Mazzocchi A, Miceli R, Paterno' E, Taverna F, Spina F, Crippa F, Farina L, Corradini P, Gianni AM, Viviani S. Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma. Leuk Res. 2017 Nov;62:91-97. doi: 10.1016/j.leukres.2017.09.018.
  11. Eichenauer DA, Becker I, Monsef I, Chadwick N, de Sanctis V, Federico M, Fortpied C, Gianni AM, Henry-Amar M, Hoskin P, Johnson P, Luminari S, Bellei M, Pulsoni A, Sydes MR, Valagussa P, Viviani S, Engert A, Franklin J. Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials.Haematologica. 2017 Oct;102(10):1748-1757. doi: 10.3324/haematol.2017.167478.
  12. Zwarthoed C, El-Galaly TC, Canepari M, Ouvrier MJ, Viotti J, Ettaiche M, Viviani S, Rigacci L, Trentin L, Rusconi C, Luminari S, Cantonetti M, Bolis S, Borra A, Darcourt J, Salvi F, Subocz E, Tajer J, Kulikowski W, Malkowski B, Zaucha JM, Gallamini A. Prognostic value of bone marrow tracer uptake pattern in baseline PET scan in Hodgkin Lymphoma: results from an International Collaborative Study. J Nucl Med. 2017 Jan 26. pii: jnumed.116.184218. doi: 10.2967.
  13. Ramsey SD, Nademanee A, Masszi T, Holowiecki J, Abidi M, Chen A, Stiff P, Viviani S, Sweetenham JW, Radford J, Zhu Y, Bonthapally V, Thomas E, Richhariya A, Hunder NN, Walewski J, Moskowitz CH. Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma. Br J Haematol. 2016 Dec;175(5):860-867. doi: 10.1111/bjh.14316.
  14. Zinzani, P.L., Vitolo, U., Viviani, S., Corradini, P., Motta, G., Tani, M., Cascavilla, N., Hohaus, S., Merli, F., Argnani, L., Broccoli, A. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma: Experience with 27 patients. Clinical Lymphoma, Myeloma and Leukemia 2015; 15 (7): 404-408. doi: 10.1016/j.clml.2015.02.023.
  15. Carlo-Stella C, Rcci F, Dalto SE, Mazza R, Malagola M., Patriarca F, Viviani S, Russo D, Giordano L, Castagna L, Corradini P, Santoro A. Brentuximab vedotin in patients with Hodgkin Lymphoma and a failed allogeneic stem cell transplantation: Results from a named patient program at four italian centers. Oncologist 2015; 20 (3): 323-328. doi: 10.1634/theoncologist.2014-0420.
  16. Farina L, Rezzonico F, Spina F, Dodero A, Mazzocchi A, Crippa F, Alessi A, Dalto S,  Viviani S, Corradini P. Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014 Dec;20(12):1982-8. doi: 10.1016/j.bbmt.2014.08.016.
  17. Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM. Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases. Clin Cancer Res. 2014 Nov 15;20(22):5641-51. doi: 10.1158/1078-0432.CCR-14-0770.
  18. Gallamini A, Barrington SF, Biggi A, Chauvie S, Kostakoglu L, Gregianin M, Meignan M, Mikhaeel GN, Loft A, Zaucha JM, Seymour JF, Hofman MS, Rigacci L, Pulsoni A, Coleman M, Dann EJ, Trentin L, Casasnovas O, Rusconi C, Brice P, Bolis S, Viviani S, Salvi F, Luminari S, Hutchings M. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica. 2014 Jun;99(6):1107-13. doi: 10.3324/haematol.2013.103218.
  19. Anastasia A, Carlo-Stella C, Corradini P, Salvi F, Rusconi C, Pulsoni A, Hohaus S, Pregno P, Viviani S, Brusamolino E, Luminari S, Giordano L, Santoro A. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. Br J Haematol. 2014 Jul;166(1):140-2. doi: 10.1111/bjh.12821.
  20. Magni M, Di Nicola M, Patti C, Scimè R, Mulè A, Rambaldi A, Intermesoli T, Viero P, Tarella C, Gueli A, Bergui L, Trentin L, Barzan A, Benedetti F, Ambrosetti A, Di Raimondo F, Chiarenza A, Parvis G, Billio A, Attolico I, Olivieri A, Montanari M, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Viviani S, Valagussa P, Gianni AM. Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. Bone Marrow Transplant. 2014 Apr;49(4):485-91. doi: 10.1038/bmt.2013.214.
  21. Devizzi L, Guidetti A, Seregni E, Passera R, Maccauro M, Magni M, Testi A, Di Nicola M, Tarella C, Matteucci P, Viviani S, Ruella M, Carlo-Stella C, Chiesa C, Cox MC, Bombardieri E, Gianni AM. Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose 90Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. J Clin Oncol. 2013 Aug 10;31(23):2974-6. doi: 10.1200/JCO.2013.50.2922.
  22. Zinzani PL, Viviani S, Anastasia A, Vitolo U, Luminari S, Zaja F, Corradini P, Spina M, Brusamolino E, Gianni AM, Santoro A, Botto B, Derenzini E, Pellegrini C, Argnani L. Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica. 2013 Aug;98(8):1232-6. doi: 10.3324/haematol.2012.083048.
  23. Viviani S, Valagussa P, Gianni A.M. The authors reply. New England Journal of Medicine, 2011; 365 (16): 1546.
  24. Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is plannedN Engl J Med. 2011 Jul 21;365(3):203-12. doi: 10.1056/NEJMoa1100340.
  25. Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di Raimondo F, Cantonetti M, Stelitano C, Feldman T, Gavarotti P, Sorasio R, Mulè A, Leone M, Rambaldi A, Biggi A, Barrington S, Fallanca F, Ficola U, Chauvie S, Gianni AM; Gruppo Italiano Terapie Innovative nei Linfomi (GITIL). Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol. 2011 Mar;152(5):551-60. doi: 10.1111/j.1365-2141.2010.08485.x.
  26. Busia A, Laffranchi A, Viviani S, Bonfante V, Villani F. Cardiopulmonary toxicity of different chemoradiotherapy combined regimens for Hodgkin's disease. Anticancer Res. 2010 Oct;30(10):4381-7.
  27. Viviani S, Di Nicola M, Bonfante V, Di Stasi A, Carlo-Stella C, Matteucci P, Magni M, Devizzi L, Valagussa P, Gianni AM. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Leuk Lymphoma. 2010 Jul;51(7):1251-9. doi: 10.3109/10428194.2010.486090.
  28. Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM, Falda M, Guidi S, Ciceri F, Bonini A, Ferrari S, Malagola M, Morello E, Milone G, Bruno B, Mordini N, Viviani S, Levis A, Giordano L, Santoro A, Corradini P; Gruppo Italiano Trapianto di Midollo Osseo. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood. 2010 May 6;115(18):3671-7. doi: 10.1182/blood-2009-12-253856.
  29. Magni M, Di Nicola M, Testi A, Cabras A, Devizzi L, Guidetti A, Matteucci P, Viviani S, Bonfante V, Carniti C, Ricca I, Carbone A, Carlo-Stella C, Gianni AM. Radioimmunotherapy and secondary leukemia: a case report. Leuk Res. 2010 Jan;34(1):e1-4. doi: 10.1016/j.leukres.2009.04.028.
  30. Villani F, Busia A, Villani M, Laffranchi A, Viviani S, Bonfante V. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease. Anticancer Res. 2009 Feb;29(2):777-83.
  31. Villani F, Busia A, Villani M, Vismara C, Viviani S, Bonfante V. Serum cytokine in response to chemo-radiotherapy for Hodgkin's disease. Tumori. 2008 Nov-Dec;94(6):803-8.
  32. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007 Aug 20;25(24):3746-52.
  33. Visco C, Nadali G, Vassilakopoulos TP, Bonfante V, Viviani S, Gianni AM, Federico M, Luminari S, Peethambaram P, Witzig TE, Pangalis G, Cabanillas F, Medeiros LJ, Sarris AH, Pizzolo G. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol. 2006 Nov;77(5):387-94.
  34. Bonadonna G, Viviani S, Bonfante V, Gianni AM, Valagussa P. Survival in Hodgkin's disease patients--report of 25 years of experience at the Milan Cancer Institute. Eur J Cancer. 2005 May;41(7):998-1006.
  35. Visco C, Vassilakopoulos TP, Kliche KO, Nadali G, Viviani S, Bonfante V, Medeiros LJ, Notti P, Rassidakis GZ, Peethambaram P, Wilder R, Witzig T, Gianni M, Bonadonna G, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH. Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. Leuk Lymphoma. 2004 Oct;45(10):2085-92.
  36. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol. 2004 Jul 15;22(14):2835-41.
  37. Herling M, Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, Kliche KO, Nadali G,     Viviani S, Bonfante V, Giardini R, Chilosi M, Kittas C, Gianni AM, Bonadonna G, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH. Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clin Cancer Res. 2003 Jun;9(6):2114-20.
  38. Villani F, Fede Catania A, Laffranchi A, Maffioli L, Viviani S, Bonfante V. Effect of an intensive chemotherapy followed by mediastinal irradiation on pulmonary and cardiac function in advanced Hodgkin's disease. Cancer Invest. 2003 Apr;21(2):185-92.
  39. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, Viviani S, Bonfante V, Nadali G, Herling M, Angelopoulou MK, Giardini R, Chilosi M, Kittas C, McDonnell TJ, Bonadonna G, Gianni AM, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood. 2002 Dec 1;100(12):3935-41.
  40. Villani F, Viola G, Vismara C, Laffranchi A, Di Russo A, Viviani S, Bonfante V. Lung function and serum concentrations of different cytokines in patients submitted to radiotherapy and intermediate/high dose chemotherapy for Hodgkin's disease. Anticancer Res. 2002 Jul-Aug;22(4):2403-8.
  41. Rassidakis GZ, Medeiros LJ, Viviani S, Bonfante V, Nadali GP, Vassilakopoulos TP, Mesina O, Herling M, Angelopoulou MK, Giardini R, Chilosi M, Kittas C, McLaughlin P, Rodriguez MA, Romaguera J, Bonadonna G, Gianni AM, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol. 2002 Mar 1;20(5):1278-87.
  42. Rassidakis GZ, Medeiros LJ, McDonnell TJ, Viviani S, Bonfante V, Nadali G, Vassilakopoulos TP, Giardini R, Chilosi M, Kittas C, Gianni AM, Bonadonna G, Pizzolo G, Pangalis GA, Cabanillas F, Sarris AH. BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome. Clin Cancer Res. 2002 Feb;8(2):488-93.
  43. Herling M, Rassidakis GZ, Viviani S, Bonfante V, Giardini R, Gianni M, Morris SW, Cabanillas F, Medeiros LJ, Sarris AH. Anaplastic lymphoma kinase (ALK) is not expressed in Hodgkin's disease: results with ALK-11 antibody in 327 untreated patients. Leuk Lymphoma. 2001 Sep-Oct;42(5):969-79.
  44. Lissoni P, Malugani F, Bonfanti A, Bucovec R, Secondino S, Brivio F, Ferrari-Bravo A, Ferrante R, Vigoré L, Rovelli F, Mandalà M, Viviani S, Fumagalli L, Gardani GS. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeost Agents. 2001 Apr-Jun;15(2):140-4.
  45. Bonfante V, Viviani S, Devizzi L, Di Russo A, Di Nicola M, Magni M, Matteucci P, Grisanti S, Valagussa P, Bonadonna G, Gianni AM. High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease. Eur J Haematol Suppl. 2001 Jul;64:51-5.
  46. Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, Fiedler F, Parra HS, Benoehr C, Pacini M, Bonadonna G, Diehl V. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol. 2000 Jul;18(13):2615-9.
  47. Viviani S, Notti P, Bonfante V, Verderio P, Valagussa P, Bonadonna G. Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the Milan Cancer Institute experience. Med Oncol. 2000 Feb;17(1):59-63.
  48. Villani F, Viviani S, Bonfante V, De Maria P, Soncini F, Laffranchi A. Late pulmonary effects in favorable stage I and IIA Hodgkin's disease treated with radiotherapy alone. Am J Clin Oncol. 2000 Feb;23(1):18-21.
  49. Villani F, Dell'Oca I, De Maria P, Viola G, Di Russo A, Viviani S, Bonfante V. Lung function and serum concentration of tumor necrosis factor-alpha, interleukin-6 and fibronectin in patients treated with ABVD chemotherapy followed by radiotherapy for mediastinal Hodgkin's disease. Anticancer Res. 1999 Sep-Oct;19(5C):4475-9.
  50. Lissoni P, Bolis S, Mandalà M, Viviani S, Pogliani E, Barni S. Blood concentrations of tumor necrosis factor-alpha in malignant lymphomas and their decrease as a predictor of disease control in response to low-dose subcutaneous immunotherapy with interleukin-2. Int J Biol Markers. 1999 Jul-Sep;14(3):167-71.
  51. Viviani S, Bonfante V, Santoro A, Zanini M, Devizzi L, Di Russo AD, Soncini F, Villani F, Ragni G, Valagussa P, Bonadonna G. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease. Cancer J Sci Am. 1999 Sep-Oct;5(5):275-82.
  52. Lissoni P, Brivio F, Viviani S, Fumagalli L. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy? J Biol Regul Homeost Agents. 1999 Apr-Jun;13(2):110-4.
  53. Bonfante V, Viviani S, Santoro A, Devizzi L, Di Russo A, Zanini M, Soncini F, Soto Parra H, Valagussa P, Bonadonna G. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. Br J Haematol. 1998 Nov;103(2):533-5.
  54. Nadali G, Tavecchia L, Zanolin E, Bonfante V, Viviani S, Camerini E, Musto P, Di Renzo N, Carotenuto M, Chilosi M, Krampera M, Pizzolo G. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. Blood. 1998 Apr 15;91(8):3011-6.
  55. Viviani S, Camerini E, Bonfante V, Santoro A, Balzarotti M, Fornier M, Devizzi L, Verderio P, Valagussa P, Bonadonna G. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications. Br J Cancer. 1998 Mar; 77(6): 992-7.
  56. Villani F, De Maria P, Bonfante V, Viviani S, Laffranchi A, Dell'oca I, Dirusso A, Zanini M. Late pulmonary toxicity after treatment for Hodgkin's disease. Anticancer Res. 1997 Nov-Dec;17(6D):4739-42.
  57. Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F, Zanini M, Valagussa P, Bonadonna G. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol. 1997 Feb;15(2):528-34.
  58. Devizzi L, Maffioli L, Bonfante V, Viviani S, Balzarini L, Gasparini M, Valagussa P, Bombardieri E, Santoro A, Bonadonna G. Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. Ann Oncol. 1997;8 Suppl 1:53-6.
  59. Balzarotti M, Tondini C, Bonfante V, Devizzi L, Viviani S, Fornier M, Santoro A. Lack of carboplatin activity in malignant lymphomas. Eur J Cancer. 1996 Dec;32A(13):2370-1.
  60. Devizzi L, Santoro A, Bonfante V, Viviani S, Bonadonna G. Vinorelbine: a new promising drug in Hodgkin's disease. Leuk Lymphoma. 1996 Aug;22(5-6):409-14.
  61. Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L, Soncini F, Valagussa P. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol. 1996 May;14(5):1421-30.
  62. Zanini M, Viviani S, Santoro A, Soncini F, Bonfante V, Devizzi L, Villani F, Castellani MR, Negretti E, Zucali R, et al. Extended-field radiotherapy in favorable stage IA-IIA Hodgkin's disease (prognostic role of stage). Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):813-9.
  63. Devizzi L, Santoro A, Bonfante V, Viviani S, Balzarini L, Valagussa P, Bonadonna G. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol. 1994 Nov;5(9):817-20.
  64. Clerici M, Ferrario E, Trabattoni D, Viviani S, Bonfanti V, Venzon DJ, Clerici E, Shearer GM, Villa ML. Multiple defects of T helper cell function in newly diagnosed patients with Hodgkin's disease. Eur J Cancer. 1994;30A(10):1464-70.
  65. Viviani S, Salvini PM, Bidoli P, Camerini E, Spinazzé S, Arienti F, Rivoltini L, Motta V. Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer. Int J Biol Markers. 1993 Jan-Mar;8(1):21-4.
  66. Bonfante V, Santoro A, Viviani S, Valagussa P, Bonadonna G. ABVD in the treatment of Hodgkin's disease. Semin Oncol. 1992 Apr;19(2 Suppl 5):38-44; discussion 44-5.
  67. Viviani S, Bidoli P, Spinazzé S, Rovelli F, Lissoni P. Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin-2 in advanced small cell lung cancer patients. J Pineal Res. 1992 Apr;12(3):114-7.
  68. Bonfante V, Santoro A, Viviani S, Zucali R, Devizzi L, Zanini M, Tesoro Tess JD, Valagussa P, Banfi A, Bonadonna G. Early stage Hodgkin's disease: ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP. Eur J Cancer. 1992;29A(1):24-9.
  69. Spinazzé S, Viviani S, Bidoli P, Rovelli F, Palmer P, Franks CR, Arienti F, Rivoltini L, Parmiani G. Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythms of cortisol and beta-endorphin in advanced small cell lung cancer patients. Tumori. 1991 Dec 31;77(6):496-9.
  70. Viviani S, Bonadonna G, Santoro A, Zanini M, Zucali R, Negretti E, Valagussa P. Alternating versus hybrid MOPP-ABVD in Hodgkin's disease: the Milan experience. Ann Oncol. 1991 Feb;2 Suppl 2:55-62.
  71. 71. Viviani S, Ragni G, Santoro A, Perotti L, Caccamo E, Negretti E, Valagussa P, Bonadonna G. Testicular dysfunction in Hodgkin's disease before and after treatment. Eur J Cancer. 1991;27(11):1389-92.
  72. Bonadonna G, Santoro A, Gianni AM, Viviani S, Siena S, Bregni M, Zucali R, Lombardi F, Bonfante V, Gianni L, et al. Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. Ann Oncol. 1991 Jan;2 Suppl 1:9-16.
  73. Sozzi G, Miozzo M, Orazi A, Calderone C, Castellano M, Viviani S, Santoro A, Pierotti MA, Della Porta G. Cytogenetic study in therapy-related myelodysplastic syndromes (t-MDS) and acute non-lymphocytic leukaemia (t-ANLL). Br J Cancer. 1990 Mar;61(3):425-8.
  74. Viviani S, Negretti E, Orazi A, Sozzi G, Santoro A, Lissoni P, Esposti G, Fraschini F. Preliminary studies on melatonin in the treatment of myelodysplastic syndromes following cancer chemotherapy. J Pineal Res. 1990;8(4):347-54.
  75. Lissoni P, Barni S, Rovelli F, Viviani S, Maestroni GJ, Conti A, Tancini G. The biological significance of soluble interleukin-2 receptors in solid tumors. Eur J Cancer. 1990 Jan;26(1):33-6.
  76. Viviani S, Santoro A, Negretti E, Bonfante V, Valagussa P, Bonadonna G. Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission. Ann Oncol. 1990;1(2):123-7.
  77. Lissoni P, Viviani S, Santoro A, Barni S, Tancini G. Serum levels of interleukin-2 in cancer patients: preliminary considerations. Int J Biol Markers. 1989 Oct-Dec;4(4):203-6.
  78. Lissoni P, Tancini G, Barni S, Viviani S, Archili C, Cattaneo G, Fiorelli G. Alterations of pineal gland and of T lymphocyte subsets in metastatic cancer patients: preliminary results. J Biol Regul Homeost Agents. 1989 Oct-Dec;3(4):181-3.
  79. Lissoni P, Barni S, Tancini G, Viviani S, Rovelli F, Rescaldani R, Fiorelli G. Effects of cancer chemotherapy on the relation between serum levels of soluble interleukin-2 receptors and CD4/CD8 ratio in patients with solid neoplasms. J Biol Regul Homeost Agents. 1989 Jul-Sep;3(3):131-3.
  80. Bonadonna G, Valagussa P, Santoro A, Viviani S, Bonfante V, Banfi A. Hodgkin's disease: the Milan Cancer Institute experience with MOPP and ABVD. Recent Results Cancer Res. 1989;117:169-74.
  81. Orazi A, Cattoretti G, Sozzi G, Miozzo M, Polli N, Delia D, Viviani S, Negretti E, Della Porta G, Rilke F. Morphologic, immunologic, and cytogenetic characteristics of secondary acute unclassifiable leukemia in Hodgkin's disease. Tumori. 1988 Aug 31;74(4):439-50.
  82. Bonadonna G, Santoro A, Viviani S, Valagussa P. Treatment strategies for Hodgkin's disease. Semin Hematol. 1988 Apr;25(2 Suppl 2):51-7.
  83. Lissoni P, Bastone A, Sala R, Mauri R, Rovelli F, Viviani S, Bajetta E, Esposti D, Esposti G, di Bella L, et al. The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels. Eur J Cancer Clin Oncol. 1987 Jul;23(7):949-57.
  84. Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnoni AM, Bonfante V, Musumeci R, Crippa F, et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol. 1987 Jan;5(1):27-37.
  85. Santoro A, Viviani S, Villarreal CJ, Bonfante V, Delfino A, Valagussa P, Bonadonna G. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep. 1986 Mar;70(3):343-8.
  86. Santoro A, Viviani S, Valagussa P, Bonfante V, Bonadonna G. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol. 1986 Mar;13(1 Suppl 1):23-6.
  87. Lissoni P, Viviani S, Bajetta E, Buzzoni R, Barreca A, Mauri R, Resentini M, Morabito F, Esposti D, Esposti G, et al. A clinical study of the pineal gland activity in oncologic patients. Cancer. 1986 Feb 15;57(4):837-42.
  88. Bajetta E, Buzzoni R, Viviani S, Vaglini M, Nava M, Bonadonna G. Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine. Am J Clin Oncol. 1985 Oct;8(5):401-5.
  89. Bajetta E, Buzzoni R, Viviani S, Villani F, Piotti P, Gasparini G, Bonadonna G. Phase II study with amsacrines (m-AMSA and m-AMSA lactate) in refractory lymphomas. Cancer Treat Rep. 1985 Sep;69(9):965-9.
  90. Ragni G, Bestetti O, Santoro A, Viviani S, Di Pietro R, De Lauretis L. Evaluation of semen and pituitary gonadotropin function in men with untreated Hodgkin's disease. Fertil Steril. 1985 Jun;43(6):927-30.
  91. Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol. 1985 May;21(5):601-5.
  92. Bonadonna G, Viviani S, Valagussa P, Bonfante V, Santoro A. Third-line salvage chemotherapy in Hodgkin's disease. Semin Oncol. 1985 Mar;12(1 Suppl 2):23-5.
  93. Santoro A, Viviani S. Results of chemotherapy of soft tissue sarcoma in adults Radiol Med. 1984 Nov;70(11):893-5.
  94. Monfardini S, Rilke F, Valagussa P, Bajetta E, Canetta R, Buzzoni R, Giardini R, Viviani S. A clinicopathologic study in advanced non-Hodgkin's lymphomas treated with sequential non-cross-resistant regimens: comparison of the working formulation with the Rappaport and Kiel classifications. Eur J Cancer Clin Oncol. 1984 May;20(5):609-17.
  95. Bonadonna G, Santoro A, Viviani S, Lombardi C, Ragni G. Gonadal damage in Hodgkin's disease from cancer chemotherapeutic regimens. Arch Toxicol Suppl. 1984;7:140-5.
  96. Bajetta E, Buzzoni R, Rilke F, Valagussa P, Rovej R, Viviani S, Lattuada A, Banfi A, Bonadonna G. Non-Hodgkin's lymphomas of Waldeyer's ring. Tumori. 1983 Apr 30;69(2):129-36.


PUBLICATIONS IN CHAPTERS AND BOOKS

  1. Bonadonna G, Viviani S, Bonfante V, Valagussa P. "Linfomi maligni" in Medicina Oncologica, pp 1381-1454 G.Bonadonna G.Robustelli della Cuna, P.Valagussa (eds), Masson, ottava edizione, Milano 2007.
  2. Bonfante V, Viviani S. "Complicanze metaboliche" in Medicina Oncologica, pp 1703-1714 G.Bonadonna G.Robustelli della Cuna (eds), P.Valagussa (eds), Masson, ottava edizione, Milano 2007.
  3. Bonadonna G, Viviani S, Bonfante V. "Linfomi maligni" in Medicina Oncologica, pp 1275-1329 G.Bonadonna G.Robustelli della Cuna, P.Valagussa (eds), Masson, settima edizione, Milano 2003.
  4. Bonfante V, Viviani S. "Complicanze metaboliche" in Medicina Oncologica, pp 1583-1592 G.Bonadonna G.Robustelli della Cuna (eds), P.Valagussa (eds), Masson, settima edizione, Milano 2003
  5. Bonfante V, Viviani S. "Complicanze metaboliche" in Medicina Oncologica, pp 1471-1480 G.Bonadonna G.Robustelli della Cuna (eds), Masson, sesta edizione, Milano 1999.
  6. Castagna L, Viviani S, Santoro A. "Stadi avanzati: oltre la MOPP e l'ABVD" in Il Linfoma di Hodgkin. Nuovi orientamenti diagnostici e terapeutici, pp 177-1786 A.Santoro, L Salvagno (eds) Piccin, Padova 1999.
  7. Viviani S, Santoro A."Il problema della sterilità" in Il Linfoma di Hodgkin. Nuovi orientamenti diagnostici e terapeutici, pp 329-338 A.Santoro, L Salvagno (eds) Piccin, Padova 1999.
  8. Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnoni AM, Bonfante V, Musumeci R, Crippa F, TesoroTess J D, Banfi A: Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease. Superiority of ABVD plus radiothaerapy versus MOPP plus radiotherapy. In “Year Book of cancer” Rc Hickey, DS Rivera (eds) 1988.
  9. Santoro A, Viviani S. Hodgkin’s disease. In “Handbook of chemotherapy in Clinical Oncology”, pp374-78. J P Droz, E Cvitkovic, J P Armand, S Khoury (eds) F.J.J.S., 1988.
  10. Viviani S:. Farmaci antitumorali. Ed Boehringer Biochem R, Milano, 1984.
  11. Casali P, Spinazzè S, Bidoli P, Viviani S, Santoro A. “Ifosfamide” in Syllabus 12° Corso di Aggiornamento in Oncologia Medica, pp507-515, Vicenza 1988.
  12. Bonfante V, Viviani S, Santoro A, Valagussa P, Bonadonna G. “Trattamenti combinati nella malattia di Hodgkin” in Radioterapia e trattamenti integrati, pp265-73. A Banfi, A Lattuada, A Santoro, R Zucali (eds). Casa Editrice Ambrosiana, Milano 1988.
  13. Viviani S; Santoro A, Bonfante V, Valagussa P, Negretti E, Bonadonna G. “Tossicità dei trattamenti combinati radio-chemioterapici nei linfomi.” In Radioterapia e trattamenti integrati, pp289-97. A Banfi, A Lattuada, A Santoro, R Zucali (eds). Casa Editrice Ambrosiana, Milano 1988.
  14. Fraschini F, Esosti D, Lissoni P, Viviani S, Esposti G, Lucini V, Ripamonti L, Scaglioni F. “The pineal function in cancer patients”. In The Pineal Gland and Cancer, pp 157-66. D Gupta, A Attanasio, R J Reiter (eds). Brain Research Promotor, Tubingen 1988.
  15. Valvo F, Viviani S, Verusio C, Bidoli P, Casali P, Santoro A. “Chemioterapia dei sarcomi uterini” in Neoplasie ginecologiche, pp49-55. U Veronesi, G B Candiani, F Di Re, A Santoro (eds). Casa Editrice Ambrosiana, Milano 1987.
  16. Santoro A, Viviani S, Zanini M, Zucali R, Valagussa P, Bonadonna G. “Trattamento della malattia di Hodgkin a  prognosi sfavorevole. In Syllabus 11° Corso di Aggiornamento in Oncologia Medica, pp 411-420, Sorrento 1986.
  17. Bonfante V, Santoro A, Bajetta E, Valagussa P, Viviani S, Buzzoni R, Bonadonna G. “Hodgkin’s disease: an overview and ABVD studies in Milan. In Bleomycin Chemotherapy, pp127-35. B J Sikic, M Rozencweig, S K Carter (eds), Academic Press 1985.
  18. Bonadonna G, Santoro A, Valagussa P, Viviani S, Zucali R, Bonfante V, Banfi A. “Current status of the Milan trials for Hodgkin’s disease in adults” in Malignat Lymphomas, pp 299-307. Martinus Nijhoff Publishing, Boston 1985.
  19. Bonfante V, Santoro A, Bajetta E, Valagussa P, Viviani S, Buzzoni R, Bonadonna G. “Non Hodgkin’s lymphomas: Milan studies. In Bleomycin Chemotherapy, pp1-6. B J Sikic, M Rozencweig, S K Carter (eds), Academic Press 1985
  20. Viviani S, Santoro A; Bonfante V, Bestetti O, Ragni G, Bonadonna G. “Tossicità gonadica dopo polichemioterapia nella malattia di Hodgkin” in Leucemie e Linfomi: Diagnosi e Terapia, pp 161-169. U Veronesi, E Polli, G Bonadonna, A Santoro, H Emanuelli (eds) Csa Editrice Ambrosiana, Milano 1985.
  21. Bonfante V, Santoro A, Villareal J R , Viviani S, Delfino A, Valagussa P, Bonadonna G. “Terapie di salvataggio nella malattia di Hodgkin: strategia e risultati. in Leucemie e Linfomi: Diagnosi e Terapia, pp 119-27. U Veronesi, E Polli, G Bonadonna, A Santoro, H Emanuelli (eds) Csa Editrice Ambrosiana, Milano 1985.
  22. Santoro A, Viviani S, Bonfante V, Verusio C, Bidoli P. “La chemioterapia dei sarcomi dei tessuti molli dell’adulto” in Syllabus 10° Corso di Aggiornamento in Oncologia Medica, pp 674-680. Roma 1984.
  23. Santoro A, Viviani S, Testa R. "Nuovi farmaci nel trattamento del carcinoma mammario" in Il carcinoma della mammella: diagnosi e terapia, pp 337-350 UVeronesi e Coll (eds), Csa editrice Ambrosiana, Milano 1983.
  24. Bajetta E, Buzzoni R, Viviani S. "Tratamiento de los linfomas no Hodgkinianos" in Revisiones de Oncologia Medica, pp 15-21 G Beretta e coll (eds), Milano 1983
  25. Santoro A, Viviani S, Cruz H J "Los sarcomas de teijdos blandos del adulto: resultados dela quimoterapia"in Revisiones de Oncologia Medica, pp 83-89 G Beretta e coll (eds), Milano 1983